<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: Risks Relating ", fill: "#fd0e35"},
{source: "4: Risks Relating ", target: "4: highly dependent on", fill: "#fd0e35"},
{source: "4: highly dependent on", target: "4: lead product", fill: "#fd0e35"},
{source: "4: Risks Relating ", target: "5: successfully", fill: "#ff004f"},
{source: "5: successfully", target: "5: commercialize", fill: "#ff004f"},
{source: "5: commercialize", target: "5: stock price would likely decline", fill: "#ff004f"},
{source: "5: successfully", target: "11: statistically significant", fill: "#536872"},
{source: "11: statistically significant", target: "11: improvement", fill: "#536872"},
{source: "11: improvement", target: "11: survival over placebo", fill: "#536872"},
{source: "11: survival over placebo", target: "11: logrank analysis", fill: "#536872"},
{source: "11: statistically significant", target: "13: dependent on", fill: "#a40000"},
{source: "13: dependent on", target: "13: readiness", fill: "#a40000"},
{source: "13: readiness", target: "13: manufacturing facility", fill: "#a40000"},
{source: "13: manufacturing facility", target: "13: New Jersey ", fill: "#a40000"},
{source: "13: New Jersey ", target: "13: facility", fill: "#a40000"},
{source: "13: facility", target: "13: as well as approval", fill: "#a40000"},
{source: "13: as well as approval", target: "13: thirdparty", fill: "#a40000"},
{source: "13: thirdparty", target: "13: manufacturer", fill: "#a40000"},
{source: "13: manufacturer", target: "13: Antigen Delivery Cassette ", fill: "#a40000"},
{source: "13: Antigen Delivery Cassette ", target: "13: preparation", fill: "#a40000"},
{source: "13: dependent on", target: "16: candidates", fill: "#8e4585"},
{source: "16: candidates", target: "16: technologies", fill: "#8e4585"},
{source: "16: technologies", target: "16: regulatory", fill: "#8e4585"},
{source: "16: regulatory", target: "16: difficult", fill: "#8e4585"},
{source: "16: candidates", target: "18: investigational", fill: "#800080"},
{source: "18: investigational", target: "18: immunotherapies", fill: "#800080"},
{source: "18: immunotherapies", target: "18: regulatory", fill: "#800080"},
{source: "18: regulatory", target: "18: development", fill: "#800080"},
{source: "18: development", target: "18: commercialization", fill: "#800080"},
{source: "18: commercialization", target: "18: immunotherapy", fill: "#800080"},
{source: "18: investigational", target: "25: must demonstrate", fill: "#002fa7"},
{source: "25: must demonstrate", target: "25: products through", fill: "#002fa7"},
{source: "25: products through", target: "25: clinical testing", fill: "#002fa7"},
{source: "25: must demonstrate", target: "27: comply with", fill: "#2c1608"},
{source: "27: comply with", target: "27: requirements which could disqualify", fill: "#2c1608"},
{source: "27: requirements which could disqualify", target: "27: ongoing clinical trials", fill: "#2c1608"},
{source: "27: comply with", target: "28: numerous unforeseen events during", fill: "#66424d"},
{source: "28: numerous unforeseen events during", target: "28: could delay", fill: "#66424d"},
{source: "28: could delay", target: "28: prevent commercialization", fill: "#66424d"},
{source: "28: prevent commercialization", target: "28: product candidate", fill: "#66424d"},
{source: "28: product candidate", target: "28: effective", fill: "#66424d"},
{source: "28: effective", target: "28: inconclusive", fill: "#66424d"},
{source: "28: inconclusive", target: "28: indicative", fill: "#66424d"},
{source: "28: indicative", target: "28: collaborators", fill: "#66424d"},
{source: "28: collaborators", target: "28: substantially", fill: "#66424d"},
{source: "28: substantially", target: "28: restructure", fill: "#66424d"},
{source: "28: restructure", target: "28: previously", fill: "#66424d"},
{source: "28: previously", target: "28: or the FDA ", fill: "#66424d"},
{source: "28: or the FDA ", target: "28: terminate clinical", fill: "#66424d"},
{source: "28: terminate clinical", target: "28: participating patients", fill: "#66424d"},
{source: "28: participating patients", target: "28: health risks", fill: "#66424d"},
{source: "28: health risks", target: "28: product candidates may", fill: "#66424d"},
{source: "28: product candidates may", target: "28: characteristics", fill: "#66424d"},
{source: "28: characteristics", target: "28: interrupt delay", fill: "#66424d"},
{source: "28: interrupt delay", target: "28: regulatory", fill: "#66424d"},
{source: "28: regulatory", target: "28: authorities", fill: "#66424d"},
{source: "28: authorities", target: "28: target indications", fill: "#66424d"},
{source: "28: numerous unforeseen events during", target: "29: clinical trials may", fill: "#e66771"},
{source: "29: clinical trials may", target: "29: support approval by", fill: "#e66771"},
{source: "29: support approval by", target: "29: FDA for Provenge ", fill: "#e66771"},
{source: "29: FDA for Provenge ", target: "29: candidates", fill: "#e66771"},
{source: "29: clinical trials may", target: "30: clinical trials", fill: "#536895"},
{source: "30: clinical trials", target: "30: product candidates", fill: "#536895"},
{source: "30: product candidates", target: "30: candidates", fill: "#536895"},
{source: "30: candidates", target: "30: and the FDA ", fill: "#536895"},
{source: "30: and the FDA ", target: "30: commercial sale", fill: "#536895"},
{source: "30: clinical trials", target: "START_HERE", fill: "#536895"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of which 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Candidate_for_Goddess">The Candidate for Goddess</a></td>
      <td>The Candidate for Goddess (Japanese: 女神候補生, Hepburn: Megami Kōhosei, lit. "Goddess Cadet") is a Japanese manga written and illustrated by Yukiru Sugisaki.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>DENDREON CORP      ITEM 1A RISK FACTORS          You  should  <font color="blue">carefully</font> consider each of the risks and <font color="blue">uncertainties</font> we     describe below and all of the other information in this annual report</td>
    </tr>
    <tr>
      <td>The     risks and <font color="blue">uncertainties</font> we describe below are not the only ones we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> of which we are currently unaware or that     we  currently  believe  to be <font color="blue">immaterial may also <font color="blue">adversely</font> affect</font> our     business</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to our Clinical and <font color="blue">Commercialization </font>Pursuits          Our near-term prospects are <font color="blue">highly <font color="blue">dependent on</font></font> Provenge, our <font color="blue">lead product</font>     candidate</td>
    </tr>
    <tr>
      <td>If  we fail to obtain FDA approval for Provenge or fail to     <font color="blue">successfully</font> <font color="blue">commercialize</font> Provenge, our business would be harmed and our     <font color="blue">stock price would likely decline</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">most advanced <font color="blue">product candidate</font></font> is Provenge, an active <font color="blue">immunotherapy</font> for     advanced prostate cancer</td>
    </tr>
    <tr>
      <td>FDA approval of Provenge depends on, among other     things, our <font color="blue">successful <font color="blue">preparation</font></font> and submission of a BLA <font color="blue">based on</font> the data     from our completed Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">manufacturing</font> protocol and     controls,  and <font color="blue">composition</font> of the product <font color="blue">and the FDA </font>finding the data     sufficient to <font color="blue">support approval</font></td>
    </tr>
    <tr>
      <td>We plan to submit a <font color="blue">BLA for Provenge </font>based     <font color="blue">primarily on</font> the <font color="blue">demonstration</font> of a <font color="blue">survival benefit</font> over placebo with     asymptomatic, metastatic androgen-<font color="blue">independent</font> prostate cancer in a Phase 3     study, D9901, <font color="blue">as well as supportive evidence on survival from</font> another <font color="blue">Phase     </font>3 study, D9902A Although the FDA has indicated that the <font color="blue">survival benefit</font>     observed in the D9901 study in <font color="blue">conjunction with</font> the <font color="blue">supportive data</font> obtained     <font color="blue">from study</font> D9902A and the absence of <font color="blue"><font color="blue">significant</font> toxicity</font> in <font color="blue">both studies</font> is     sufficient to serve as the clinical basis of a BLA submission for Provenge,     the FDA <font color="blue">may ultimately</font> determine the data from these <font color="blue">two studies fails</font> to     provide sufficient evidence of efficacy for Provenge and may require that we     provide data from <font color="blue">ongoing <font color="blue"><font color="blue">clinical trial</font>s</font></font>, or commence <font color="blue">additional</font> trials to     provide further supporting <font color="blue">clinical data</font> and/or testing in a <font color="blue">wider patient</font>     population</td>
    </tr>
    <tr>
      <td>Survival was not originally a primary or <font color="blue">secondary endpoint</font> in     either of these studies</td>
    </tr>
    <tr>
      <td>Neither study achieved <font color="blue">statistical significance on</font>     its <font color="blue">prespecified primary endpoint</font>, time to <font color="blue">disease progression</font></td>
    </tr>
    <tr>
      <td>In addition,     our  D9902A  Phase  3  study  did not show a <font color="blue">statistically <font color="blue">significant</font></font>     <font color="blue">improvement</font> in <font color="blue">survival over placebo</font> in a log-rank analysis</td>
    </tr>
    <tr>
      <td>For example, the CMC portion of our BLA is <font color="blue">dependent on</font> the     <font color="blue">readiness</font> of our <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facility</font></font> in New Jersey, <font color="blue">as well as approval</font>     of the <font color="blue">facility</font> of Diosynth, our third-party component <font color="blue"><font color="blue">manufacture</font>r</font> for the     <font color="blue">Antigen Delivery Cassette </font>used in the <font color="blue">preparation</font> of Provenge</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Difficulties </font>    </font>or delays in <font color="blue">qualification</font> of these <font color="blue">facilities</font>, or in the <font color="blue">manufacture</font> or     supply  of  <font color="blue"><font color="blue">necessary</font> <font color="blue">components</font></font> for the <font color="blue">manufacture</font> of Provenge could     <font color="blue"><font color="blue">significant</font>ly delay</font> the <font color="blue"><font color="blue">application</font> process</font> for our BLA Even if we receive     FDA approval, we might not be successful in <font color="blue">commercializing</font> Provenge</td>
    </tr>
    <tr>
      <td>If any     of these things occur, our business would be harmed and the price of our     <font color="blue"><font color="blue">common stock</font> would likely decline</font></td>
    </tr>
    <tr>
      <td>Provenge and our other product <font color="blue">candidates</font> are <font color="blue">based on</font> novel <font color="blue">technologies</font>,     which may raise new <font color="blue">regulatory</font> issues that <font color="blue">could delay</font> or make FDA approval     more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>The  process of obtaining required FDA and other <font color="blue">regulatory</font> approvals,     including <font color="blue">foreign approvals</font>, is expensive, often takes many years and can     vary  <font color="blue"><font color="blue">substantially</font> based upon</font> the type, <font color="blue">complexity</font> and novelty of the     products  involved</td>
    </tr>
    <tr>
      <td><font color="blue">Provenge  </font>and  our  other  <font color="blue">investigational</font> active     <font color="blue">immunotherapies</font>  are  novel;  therefore,  <font color="blue">regulatory</font> agencies may lack     experience with them, which may lengthen the <font color="blue">regulatory</font> review process,     increase our <font color="blue">development</font> costs and delay or prevent <font color="blue">commercialization</font> of     Provenge and our other active <font color="blue">immunotherapy</font> <font color="blue">products under</font> <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>To date, the FDA has not approved for <font color="blue">commercial sale</font> in the <font color="blue"><font color="blue">United States </font>    </font>any active <font color="blue">immunotherapy</font> designed to stimulate an immune response against     cancer</td>
    </tr>
    <tr>
      <td>Consequently,  there  is  no  precedent  for  the  successful     <font color="blue">commercialization</font> of products <font color="blue">based on</font> our <font color="blue">technologies</font> in this area</td>
    </tr>
    <tr>
      <td>In     addition, we have had only limited experience in filing and pursuing the     <font color="blue"><font color="blue">application</font>s <font color="blue">necessary</font></font> to gain <font color="blue">regulatory</font> approvals for marketing and                                           16     ______________________________________________________________________       <font color="blue">commercial sale</font>, which may impede our ability to obtain FDA approvals</td>
    </tr>
    <tr>
      <td>We     will not be able to <font color="blue">commercialize</font> any of our <font color="blue"><font color="blue">potential product</font>s until</font> we     obtain FDA approval</td>
    </tr>
    <tr>
      <td>If testing of a <font color="blue">particular <font color="blue">product candidate</font></font> does not <font color="blue">yield successful</font>     results, then we will be unable to <font color="blue">commercialize</font> that product</td>
    </tr>
    <tr>
      <td>Our  product  <font color="blue">candidates</font> in <font color="blue"><font color="blue"><font color="blue">clinical trial</font>s</font> must meet rigorous testing</font>     standards</td>
    </tr>
    <tr>
      <td>We <font color="blue">must <font color="blue">demonstrate</font></font> the safety and efficacy of our potential     <font color="blue">products through</font> extensive preclinical and <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>Clinical trials     are subject to continuing oversight by <font color="blue">government</font>al <font color="blue">regulatory</font> <font color="blue">authorities</font>     and <font color="blue">institutional review boards</font> and must meet the <font color="blue">requirements</font> of these     <font color="blue">authorities</font> in the United States, including those for <font color="blue">informed consent</font> and     good  clinical  practices</td>
    </tr>
    <tr>
      <td>We  may  not  be able to <font color="blue">comply with</font> these     <font color="blue">requirements</font>, which could disqualify completed or <font color="blue">ongoing <font color="blue"><font color="blue">clinical trial</font>s</font></font></td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">numerous unforeseen events during</font>, or as a result of, the     testing process that <font color="blue">could delay</font> or prevent <font color="blue">commercialization</font> of Provenge or     our other product <font color="blue">candidates</font>, including the following:           •   safety and efficacy results from human <font color="blue"><font color="blue"><font color="blue">clinical trial</font>s</font> may</font> show the     <font color="blue">product candidate</font> to be less <font color="blue">effective</font> or safe than desired or those results     may not be replicated in later <font color="blue"><font color="blue">clinical trial</font>s</font>;           •   the results of <font color="blue">preclinical studies</font> may be <font color="blue">inconclusive</font> or they may not     be <font color="blue">indicative</font> of results that will be obtained in human <font color="blue"><font color="blue">clinical trial</font>s</font>;           •   after reviewing relevant information, including pre<font color="blue">clinical testing</font> or     human <font color="blue">clinical trial</font> results, we or our <font color="blue"><font color="blue">collaborator</font>s</font> may abandon or     <font color="blue">substantially</font> <font color="blue">restructure</font> projects that we might <font color="blue">previously</font> have believed to     be promising;           •   we, our <font color="blue"><font color="blue">collaborator</font>s</font> <font color="blue">or the FDA </font>may suspend or <font color="blue">terminate clinical</font>     trials if the <font color="blue">participating patients</font> are being exposed to unacceptable     <font color="blue">health risks</font> or for other reasons; and           •   the effects of our product <font color="blue">candidates</font> may not be the desired effects     or may include undesirable side effects or other <font color="blue">characteristics</font> that     interrupt, delay or cause us, our <font color="blue"><font color="blue">collaborator</font>s</font> <font color="blue">or the FDA </font>to halt clinical     trials or cause the FDA or foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> to deny approval     of the <font color="blue">product candidate</font> for any or all <font color="blue">target indications</font></td>
    </tr>
    <tr>
      <td>Data from our <font color="blue"><font color="blue"><font color="blue">clinical trial</font>s</font> may</font> not be sufficient to <font color="blue">support approval</font> by     the <font color="blue">FDA for Provenge </font>or our other product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">clinical trial</font>s</font> of     Provenge or our other product <font color="blue">candidates</font> may not be completed as or when     planned, <font color="blue">and the FDA </font>may not approve any of our product <font color="blue">candidates</font> for     <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">demonstrate</font> the safety or efficacy of a     <font color="blue">product candidate</font> to the <font color="blue">satisfaction</font> of the FDA, this will delay or prevent     <font color="blue">regulatory</font> approval of that <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Therefore, any delay in     obtaining,  or <font color="blue">inability</font> to obtain, FDA approval of any of our product     <font color="blue">candidates</font> could <font color="blue">materially harm</font> our business and cause our stock price to     decline</td>
    </tr>
    <tr>
      <td>The FDA or its <font color="blue">Advisory Committee </font>may determine our <font color="blue"><font color="blue">clinical trial</font>s</font> data     regarding safety or efficacy are insufficient for <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>We <font color="blue">discuss with</font> and obtain guidance from <font color="blue">regulatory</font> <font color="blue">authorities</font> on certain     of our clinical <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">discussions</font> are not binding     <font color="blue">obligations</font>  on  the  part  of  <font color="blue">regulatory</font>  <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Under certain     <font color="blue">circumstances</font>,  <font color="blue">regulatory</font>  <font color="blue">authorities</font> may revise or <font color="blue">retract previous</font>     guidance  during  the  course  of our <font color="blue">clinical <font color="blue">activities</font></font> or after the     <font color="blue">completion</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">may also disqualify</font> a clinical     trial in whole or in part <font color="blue">from consideration</font> in support of approval of a     <font color="blue">potential product</font> for <font color="blue">commercial sale</font> or <font color="blue">otherwise deny approval</font> of that     product</td>
    </tr>
    <tr>
      <td>Even if we obtain <font color="blue">successful clinical safety</font> and <font color="blue">efficacy data</font>, we     may be required to conduct <font color="blue">additional</font>, expensive trials to obtain <font color="blue">regulatory</font>     approval</td>
    </tr>
    <tr>
      <td>Prior to <font color="blue">regulatory</font> approval, the FDA may elect to obtain advice     from  outside  experts  regarding  scientific  issues and/or marketing     <font color="blue"><font color="blue">application</font>s under</font> FDA review</td>
    </tr>
    <tr>
      <td>These <font color="blue">outside experts</font> are <font color="blue">convened through</font>     the FDA’s <font color="blue">Advisory Committee </font>process</td>
    </tr>
    <tr>
      <td>An <font color="blue">Advisory Committee </font>will report to     the FDA and make <font color="blue">recommendations</font></td>
    </tr>
    <tr>
      <td>Views of the <font color="blue">Advisory Committee </font>may differ                                           17     ______________________________________________________________________       from those <font color="blue">of the FDA </font>We will not know whether Provenge will be <font color="blue">reviewed by</font>     an <font color="blue">Advisory Committee </font><font color="blue">until sometime during</font> the FDA’s review of our BLA for     Provenge</td>
    </tr>
    <tr>
      <td>If  <font color="blue">Provenge  </font>is  <font color="blue">reviewed by</font> an Advisory Committee, we may     experience delays in obtaining approval by the FDA because of the time     <font color="blue">associated with</font> the Advisory Committee’s process, or we may not obtain     approval of the BLA from the FDA because the <font color="blue">Advisory Committee </font>advises     against it</td>
    </tr>
    <tr>
      <td>We may take longer to complete our <font color="blue"><font color="blue">clinical trial</font>s</font> than we project, or we     may not be able to complete them at all</td>
    </tr>
    <tr>
      <td>A  number of factors, including <font color="blue">unexpected delays</font> in the <font color="blue">initiation</font> of     clinical sites, slower than projected <font color="blue">enrollment</font>, <font color="blue">competition with</font> ongoing     <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">scheduling conflicts with participating clinicians</font>,     <font color="blue">regulatory</font> <font color="blue">requirements</font>, limits on <font color="blue">manufacturing</font> capacity and failure of a     <font color="blue">product candidate</font> to meet required standards for <font color="blue">administration</font> to humans     may cause <font color="blue"><font color="blue">significant</font> delays</font> in the <font color="blue">completion</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In     addition, it may take <font color="blue">longer than</font> we project to achieve <font color="blue">study endpoints</font> and     complete <font color="blue">data analysis</font> for a trial</td>
    </tr>
    <tr>
      <td>Even if our product <font color="blue">candidates</font> proceed     <font color="blue">successfully</font> through <font color="blue"><font color="blue">clinical trial</font>s</font> and receive <font color="blue">regulatory</font> approval, there     is no guarantee that an <font color="blue">approved product</font> can be <font color="blue">manufacture</font>d in commercial     <font color="blue">quantities at <font color="blue">reasonable cost</font></font> or that such a <font color="blue">product will</font> be <font color="blue">successfully</font>     marketed</td>
    </tr>
    <tr>
      <td>We rely on academic <font color="blue">institutions</font>, physician practices and <font color="blue">clinical research</font>     <font color="blue">organizations</font>  to conduct, supervise or monitor some or all aspects of     <font color="blue"><font color="blue">clinical trial</font>s</font> involving our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">less control over</font>     the timing and other aspects of these <font color="blue"><font color="blue">clinical trial</font>s</font> than if we conducted     the monitoring and <font color="blue">supervision entirely on</font> our own</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> not     perform their <font color="blue">responsibilities</font> for our <font color="blue"><font color="blue">clinical trial</font>s</font> on our anticipated     schedule  or  <font color="blue">consistent</font>  with a <font color="blue">clinical <font color="blue">trial protocol</font></font> or applicable     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We also rely on <font color="blue">clinical research</font> <font color="blue">organizations</font> to perform much     of our <font color="blue">data <font color="blue">management</font></font> and analysis</td>
    </tr>
    <tr>
      <td>They may not provide these <font color="blue">services as</font>     required or in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>If we fail to commence, complete or experience delays in any of our other     present or planned <font color="blue"><font color="blue">clinical trial</font>s</font>, our ability to conduct our business as     currently  planned <font color="blue">could materially suffer</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font> costs will     increase if we experience delays in our ability to submit a <font color="blue">BLA for <font color="blue"><font color="blue">Provenge  </font>   </font></font>or if we are required to complete <font color="blue">additional</font> or larger <font color="blue"><font color="blue">clinical trial</font>s</font> for     Provenge prior to FDA approval or <font color="blue">with respect</font> to other product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If  the delays or costs are <font color="blue">significant</font>, our financial results and our     ability to <font color="blue">commercialize</font> Provenge or our other product <font color="blue">candidates</font> will be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>If we encounter <font color="blue">difficult</font>ies enrolling patients in our <font color="blue"><font color="blue">clinical trial</font>s</font>, our     <font color="blue">trials could</font> be delayed or otherwise <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Clinical trials for our product <font color="blue">candidates</font> may require that we identify and     enroll a large number of <font color="blue">patients with</font> the <font color="blue">disease under investigation</font></td>
    </tr>
    <tr>
      <td>We     may not be able to enroll a sufficient number of patients to complete our     <font color="blue"><font color="blue">clinical trial</font>s</font> in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>We have in the past experienced some     <font color="blue">difficult</font>y  in  <font color="blue">enrollment</font>  in our <font color="blue"><font color="blue">clinical trial</font>s</font> due to the criteria     specified for <font color="blue">eligibility</font> for these trials, and we <font color="blue">may encounter</font> these     <font color="blue">difficult</font>ies  in our <font color="blue">ongoing <font color="blue"><font color="blue">clinical trial</font>s</font></font> for Provenge or our other     product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Patient <font color="blue">enrollment</font> is <font color="blue">affected by factors</font> including:           •   design of the <font color="blue">trial protocol</font>;           •   the size of the <font color="blue">patient population</font>;           •   <font color="blue">eligibility</font> criteria for the study in question;           •   perceived risks and benefits of the <font color="blue">product candidate</font> under study;           •   <font color="blue">availability</font> of <font color="blue">competing therapies</font> and <font color="blue"><font color="blue">clinical trial</font>s</font>;           •   efforts to facilitate timely <font color="blue">enrollment</font> in <font color="blue"><font color="blue">clinical trial</font>s</font>;                                           18     ______________________________________________________________________         •   <font color="blue">patient referral practices</font> of physicians;           •   the ability to <font color="blue">monitor patients adequately during</font> and after treatment;     and           •   proximity and <font color="blue">availability</font> of <font color="blue"><font color="blue">clinical trial</font> sites</font> for prospective     patients</td>
    </tr>
    <tr>
      <td>If we have <font color="blue">difficult</font>y enrolling a sufficient number of patients to conduct     our <font color="blue"><font color="blue">clinical trial</font>s</font> as planned, we may need to delay or <font color="blue">terminate ongoing</font> or     planned <font color="blue"><font color="blue">clinical trial</font>s</font>, either of <font color="blue">which would</font> have a negative effect on our     business</td>
    </tr>
    <tr>
      <td>We must expand our <font color="blue">operations</font> to <font color="blue">commercialize</font> our products, which we may     not be able to do</td>
    </tr>
    <tr>
      <td>We will need to expand and <font color="blue">effective</font>ly manage our <font color="blue">operations</font> and <font color="blue">facilities</font>     and develop the <font color="blue"><font color="blue">necessary</font> <font color="blue">infrastructure</font></font> to <font color="blue">commercialize</font> Provenge and     pursue <font color="blue">development</font> of our other product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We will need to add     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">capabilities</font></font>, information <font color="blue"><font color="blue">technology</font> systems</font>, a <font color="blue">distribution</font>     network and personnel related to these functions</td>
    </tr>
    <tr>
      <td>In August 2005, we entered     into  an <font color="blue">agreement</font> to lease a <font color="blue">facility</font> in <font color="blue">New Jersey </font>that <font color="blue">will provide</font>     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">capabilities</font></font> and related supporting <font color="blue">facilities</font>, as well as     <font color="blue">clean rooms</font>, the build-out of which is estimated to <font color="blue">extend through</font> mid-2006</td>
    </tr>
    <tr>
      <td>This <font color="blue">facility</font> will be inspected by the FDA as part of the BLA review</td>
    </tr>
    <tr>
      <td>We     will also need to add quality control, quality assurance, marketing and     <font color="blue">sales personnel</font>, and personnel in all other areas of our <font color="blue">operations</font>, which     may  strain  our existing managerial, operational, financial and other     resources</td>
    </tr>
    <tr>
      <td>Our failure to ready our <font color="blue">manufacturing</font> <font color="blue">facilities</font> on a timely     basis during 2006 <font color="blue">could delay</font> our submission of the CMC portion of our BLA     and effect the overall timing of the submission of a completed BLA         We have no experience in commercial-scale <font color="blue">manufacturing</font>, the <font color="blue">installation</font>     and  <font color="blue">management</font>  of large-scale information <font color="blue"><font color="blue">technology</font> systems</font>, or the     <font color="blue">management</font> of a large-scale <font color="blue">distribution</font> network</td>
    </tr>
    <tr>
      <td>We also have no experience     in sales, marketing or <font color="blue">distribution</font> of products in <font color="blue">commercial quantities</font></td>
    </tr>
    <tr>
      <td>As     we begin to build our <font color="blue">sales capability</font> in anticipation of the approval and     <font color="blue">commercial launch</font> of Provenge, we may be unable to <font color="blue">successfully</font> recruit an     adequate number of <font color="blue">qualified sales representatives</font> or retain a <font color="blue">third party</font>     to provide sales, marketing or <font color="blue">distribution</font> resources</td>
    </tr>
    <tr>
      <td>If we fail to manage our growth <font color="blue">effective</font>ly, recruit required personnel or     expand  our <font color="blue">operations</font> within our planned time and budget, our product     <font color="blue">development</font> and <font color="blue">commercialization</font> efforts for Provenge or our other product     <font color="blue">candidates</font> could be curtailed or delayed</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to our Financial Position and Need for <font color="blue">Additional </font>Financing          We have a history of operating losses</td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur losses</font>     for the near future, and we <font color="blue">may never become profitable</font></td>
    </tr>
    <tr>
      <td><font color="blue">At <font color="blue">December </font></font>31, 2005, we had an <font color="blue">accumulated deficit</font> of dlra300dtta7 million</td>
    </tr>
    <tr>
      <td>We do     not have any products that <font color="blue">generate revenue from commercial product sales</font></td>
    </tr>
    <tr>
      <td><font color="blue">Operating </font>losses have resulted <font color="blue">principally from costs incurred</font> in pursuing     our research and <font color="blue">development</font> programs, <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">manufacturing</font>,     marketing and general and <font color="blue">administrative expenses</font> in support of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We do not expect to achieve <font color="blue">commercial product sales during</font> the next year,     and we may never achieve this goal</td>
    </tr>
    <tr>
      <td>We expect to incur <font color="blue">additional</font> operating     <font color="blue">losses over</font> the <font color="blue">next few years</font>, and these losses may increase <font color="blue">significant</font>ly     as  we  continue  preclinical  research and <font color="blue"><font color="blue">clinical trial</font>s</font>, apply for     <font color="blue">regulatory</font> approvals, expand our <font color="blue">operations</font> and develop the <font color="blue">manufacturing</font>     and <font color="blue">marketing <font color="blue">infrastructure</font></font> to support <font color="blue">commercialization</font> of Provenge and     our other <font color="blue">potential product</font> <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>These losses have caused and may     continue to cause our <font color="blue">stockholders</font>’ equity and working capital to decrease</td>
    </tr>
    <tr>
      <td>We may not be successful in <font color="blue">commercializing</font> any of our product <font color="blue">candidates</font>,     and  our  <font color="blue">operations</font>  may not be <font color="blue">profitable even</font> if any of our product     <font color="blue">candidates</font> are <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       We  are likely to require <font color="blue">additional</font> funding, and our <font color="blue">future access</font> to     capital is uncertain</td>
    </tr>
    <tr>
      <td>It  is  expensive  to  develop and <font color="blue">commercialize</font> cancer <font color="blue">immunotherapy</font>,     monoclonal  antibody and small molecule product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We plan to     continue to simultaneously conduct <font color="blue"><font color="blue">clinical trial</font>s</font> and pre<font color="blue">clinical research</font>     for a number of product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> efforts may not     lead to commercial products, either because our product <font color="blue">candidates</font> fail to     be  found  safe or <font color="blue">effective</font> in <font color="blue"><font color="blue">clinical trial</font>s</font> or because we lack the     <font color="blue">necessary</font>  financial or other resources or <font color="blue">relationships</font> to pursue our     programs through <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">commercialize</font>d, a <font color="blue">product may</font>     not achieve revenues that exceed the costs of producing and selling it</td>
    </tr>
    <tr>
      <td>Our     capital and <font color="blue">future cash flow may</font> not be sufficient to support the expenses     of our <font color="blue">operations</font> and we may need to raise <font color="blue">additional</font> capital depending on a     number of factors, including the following:           •   timing of preparing and supporting a <font color="blue">BLA for FDA </font>approval of Provenge;           •   the costs of developing the <font color="blue">manufacturing</font>, marketing and other     <font color="blue">supporting resources</font> and systems to support FDA approval of Provenge;           •   our timetable and costs for the <font color="blue">development</font> of marketing,     <font color="blue">manufacturing</font>, information <font color="blue">technology</font> and other <font color="blue">infrastructure</font> and     <font color="blue">activities</font> related to the <font color="blue">commercialization</font> of Provenge;           •   the rate of progress and cost of our research and <font color="blue">development</font> and     <font color="blue">clinical trial</font> <font color="blue">activities</font>;           •   the amount and timing of payments we receive from <font color="blue"><font color="blue">collaborator</font>s</font> or     changes in or <font color="blue">terminations</font> of our <font color="blue">existing <font color="blue">collaboration</font></font> and licensing     <font color="blue">arrangements</font>;           •   the <font color="blue">introduction</font> of <font color="blue">competing products</font> and other <font color="blue">adverse market</font>     <font color="blue">development</font>s; and           •   whether we <font color="blue">enter into</font> a <font color="blue">collaboration</font> for the <font color="blue">commercialization</font> of     Provenge</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">additional</font> financing on favorable terms or at     all</td>
    </tr>
    <tr>
      <td>If we are unable to raise <font color="blue">additional</font> funds, we may have to delay,     reduce  or  eliminate  some of our <font color="blue"><font color="blue">clinical trial</font>s</font> and our <font color="blue">development</font>     programs</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> funds by issuing equity securities, further     dilution to our <font color="blue"><font color="blue">existing <font color="blue">stockholders</font></font> will</font> result</td>
    </tr>
    <tr>
      <td>We may elect to issue <font color="blue">additional</font> shares of our <font color="blue">common stock</font>, which could     result in <font color="blue">further dilution</font> to our <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may sell up</font> to dlra98dtta2 million of our <font color="blue"><font color="blue">common stock</font> under</font> our outstanding     <font color="blue">shelf <font color="blue">registration</font> statement</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">sales under</font> this or any <font color="blue">future shelf</font>     <font color="blue">registration</font> statement will depend <font color="blue">primarily on</font> the <font color="blue">market price</font> of our     <font color="blue">common stock</font>, the interest in our <font color="blue">company by institutional investors</font> and our     cash needs</td>
    </tr>
    <tr>
      <td>In addition, we may register <font color="blue">additional</font> shares with the SEC for     sale in the future</td>
    </tr>
    <tr>
      <td>Each of our issuances of <font color="blue">common stock</font> to investors under     a <font color="blue">registration</font> statement or otherwise will <font color="blue">proportionately</font> decrease our     <font color="blue">existing <font color="blue">stockholders</font></font>’ percentage ownership of our total outstanding equity     interests and may reduce our stock price</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related to Regulation </font>of our Industry          The  industry  within  which we operate and our business is subject to     extensive regulation, which is costly, time consuming and may subject us to     <font color="blue">unanticipated delays</font></td>
    </tr>
    <tr>
      <td>Our  business,  including  preclinical  studies,  clinical  trials and     <font color="blue">manufacturing</font>, is subject to extensive <font color="blue">regulation by</font> the FDA and comparable     <font color="blue">authorities</font>  outside  the  United  States</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font><font color="blue">studies involve</font>     <font color="blue">laboratory evaluation</font> of product <font color="blue">characteristics</font> and <font color="blue">animal studies</font> to     assess the efficacy and safety of a <font color="blue">potential product</font></td>
    </tr>
    <tr>
      <td>The FDA regulates     <font color="blue"><font color="blue">preclinical studies</font> under</font> a series of <font color="blue">regulations</font> called the current Good     Laboratory Practices</td>
    </tr>
    <tr>
      <td>If we violate these <font color="blue">regulations</font>, the FDA, in some     cases,  may not accept the studies and require that we replicate those     studies</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       An IND must become <font color="blue">effective</font> before human <font color="blue"><font color="blue"><font color="blue">clinical trial</font>s</font> may</font> commence</td>
    </tr>
    <tr>
      <td>The     IND <font color="blue">application</font> is automatically <font color="blue">effective</font> 30 days after <font color="blue">receipt by</font> the FDA     unless, before that time, the FDA <font color="blue">raises concerns</font> or <font color="blue">questions about</font> the     product’s safety profile or the design of the <font color="blue">trials as described</font> in the     <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>In the latter case, any outstanding concerns must be resolved     with the FDA before <font color="blue"><font color="blue">clinical trial</font>s</font> can proceed</td>
    </tr>
    <tr>
      <td>Thus, the submission of an     IND may not result in FDA <font color="blue">authorization</font> to commence <font color="blue"><font color="blue">clinical trial</font>s</font> in any     given case</td>
    </tr>
    <tr>
      <td>After <font color="blue">authorization</font> is received, the FDA retains authority to     place the IND, and <font color="blue"><font color="blue">clinical trial</font>s</font> under that IND, on clinical hold</td>
    </tr>
    <tr>
      <td>If we     are  unable to commence <font color="blue"><font color="blue">clinical trial</font>s</font> or <font color="blue"><font color="blue">clinical trial</font>s</font> are delayed     <font color="blue">indefinitely</font>, we would be unable to develop our product <font color="blue">candidates</font> and our     business would be <font color="blue"><font color="blue">materially harm</font>ed</font></td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization </font>of our product <font color="blue">candidates</font> in the <font color="blue">United States </font>requires     FDA  approval, which may not be granted, and foreign <font color="blue">commercialization</font>     requires similar approvals</td>
    </tr>
    <tr>
      <td>The FDA can delay, limit or <font color="blue">withhold approval</font> of a <font color="blue">product candidate</font> for     many reasons, including the following:           •   a <font color="blue">product candidate</font> may not <font color="blue">demonstrate</font> sufficient safety in human     trials or efficacy in treatment;           •   the FDA may interpret data from pre<font color="blue">clinical testing</font> and clinical     trials in <font color="blue">different ways than</font> we interpret the data or may require     <font color="blue">additional</font> and/or different categories of data than what we obtained in our     <font color="blue"><font color="blue">clinical trial</font>s</font>;           •   the FDA may require <font color="blue">additional</font> information about the efficacy, safety,     purity, stability, identity or <font color="blue">functionality</font> of a <font color="blue">product candidate</font>;           •   the FDA may not approve our <font color="blue">manufacturing</font> processes or <font color="blue">facilities</font> or     the processes or <font color="blue">facilities</font> of our <font color="blue"><font color="blue">collaborator</font>s</font> or contract <font color="blue"><font color="blue">manufacture</font>r</font>s;     and           •   the FDA may change its <font color="blue">approval policies</font> or adopt new <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">also may approve</font> a product for <font color="blue">fewer indications than</font> are requested     or <font color="blue">may condition approval on</font> the performance of post-approval clinical     studies</td>
    </tr>
    <tr>
      <td>Even if we receive FDA and other <font color="blue">regulatory</font> approvals, our products     <font color="blue">may later exhibit adverse effects</font> that limit or prevent their <font color="blue">widespread use</font>     or that force us to withdraw those <font color="blue">products from</font> the market</td>
    </tr>
    <tr>
      <td>Any product and     its <font color="blue"><font color="blue">manufacture</font>r</font> <font color="blue">will continue</font> to be subject to strict <font color="blue">regulations</font> after     approval, including but not limited to, the labeling, packaging, adverse     event reporting, storage, advertising, promotion and record-keeping</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">problems with</font> an <font color="blue">approved product</font> or any violation of <font color="blue">regulations</font> could     result in <font color="blue"><font color="blue">restrictions</font> on</font> the product, including its <font color="blue">withdrawal from</font> the     market</td>
    </tr>
    <tr>
      <td>The process of obtaining approvals in foreign countries is subject     to delay and failure for many of the <font color="blue">same reasons</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> foreign <font color="blue">regulatory</font> <font color="blue">requirements</font> governing human     <font color="blue"><font color="blue">clinical trial</font>s</font> and marketing approval for product <font color="blue">candidates</font> could prevent     us from selling our products in foreign markets, which may <font color="blue">adversely</font> affect     our operating results and financial condition</td>
    </tr>
    <tr>
      <td>The  <font color="blue">requirements</font>  governing  the  conduct of <font color="blue"><font color="blue">clinical trial</font>s</font>, product     licensing, pricing and <font color="blue"><font color="blue">reimbursement</font> outside</font> the <font color="blue">United States </font><font color="blue">vary greatly</font>     <font color="blue">from country</font> to country</td>
    </tr>
    <tr>
      <td>The time required to obtain approvals outside the     <font color="blue">United States </font><font color="blue">may differ from</font> that required to obtain FDA approval</td>
    </tr>
    <tr>
      <td>We may     not  obtain foreign <font color="blue">regulatory</font> approvals on a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>Approval by the FDA does not ensure approval by <font color="blue">regulatory</font> <font color="blue">authorities</font> in     other countries, and approval by one foreign <font color="blue">regulatory</font> authority does not     ensure approval by <font color="blue">regulatory</font> <font color="blue">authorities</font> in other countries or by the FDA     and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> could require <font color="blue">additional</font> testing</td>
    </tr>
    <tr>
      <td><font color="blue">Failure     </font>to <font color="blue">comply with</font> these <font color="blue">regulatory</font> <font color="blue">requirements</font> or obtain required approvals     could impair our ability to develop foreign markets for our products and may     have a material adverse effect on our results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       Even if approved, Provenge and any other product we may <font color="blue">commercialize</font> and     market may be <font color="blue">later withdrawn from</font> the market or subject to promotional     <font color="blue">limitations</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain the labeling claims <font color="blue">necessary</font> or desirable for     the  promotion  of  our products</td>
    </tr>
    <tr>
      <td>We may also be required to undertake     post-marketing  <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If the results of such post-marketing     studies are not satisfactory, the FDA may withdraw marketing <font color="blue">authorization</font>     or may condition continued marketing on commitments from us that may be     expensive and/or time consuming to fulfill</td>
    </tr>
    <tr>
      <td>In addition, if we or others     identify adverse side effects after any of our products are on the market,     or if <font color="blue">manufacturing</font> problems occur, <font color="blue">regulatory</font> approval may be withdrawn and     <font color="blue">re<font color="blue">formulation</font></font>  of our products, <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font>, changes in     labeling  of our products and <font color="blue">additional</font> marketing <font color="blue">application</font>s may be     required</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> and amount of <font color="blue">reimbursement</font> for our product <font color="blue">candidates</font> and     the manner in <font color="blue">which <font color="blue">government</font></font> and <font color="blue">private payers may reimburse</font> for our     <font color="blue">potential product</font>s is uncertain</td>
    </tr>
    <tr>
      <td>We expect that many of the patients who <font color="blue">seek treatment with</font> Provenge or any     other of our products that are approved for <font color="blue">marketing will</font> be eligible for     Medicare benefits</td>
    </tr>
    <tr>
      <td>Other <font color="blue">patients may</font> be <font color="blue">covered by <font color="blue">private health</font></font> plans or     uninsured</td>
    </tr>
    <tr>
      <td>The  <font color="blue">application</font>  of  existing  <font color="blue">Medicare  </font><font color="blue">regulations</font>, and     <font color="blue">interpretive</font> coverage and payment de<font color="blue">terminations</font> to newly <font color="blue">approved product</font>s,     <font color="blue"><font color="blue">especially</font> novel products such as ours</font>, is uncertain, and those <font color="blue">regulations</font>     and  <font color="blue">interpretive</font>  de<font color="blue">terminations</font>  are subject to change</td>
    </tr>
    <tr>
      <td>The <font color="blue">Medicare  </font>   Prescription  Drug,  Improvement,  and  Modernization  Act  (“<font color="blue">Medicare  </font>   Modernization Act”), enacted in <font color="blue">December </font>2003, provides for a change in     <font color="blue">reimbursement</font> methodology that reduces the Medicare <font color="blue">reimbursement</font> rates for     many drugs, including oncology <font color="blue">therapeutic</font>s, which may <font color="blue">adversely</font> affect     <font color="blue">reimbursement</font> for Provenge, if it is approved for sale, or our other product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If  we  are unable to obtain or retain <font color="blue">adequate levels</font> of     <font color="blue">reimbursement</font> from Medicare or from <font color="blue">private health</font> plans, our ability to     sell Provenge and our other <font color="blue">potential product</font>s will be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Medicare <font color="blue">regulations</font> and <font color="blue">interpretive</font> de<font color="blue">terminations</font> also may determine who     may  be reimbursed for <font color="blue">certain services</font></td>
    </tr>
    <tr>
      <td>This may <font color="blue">adversely</font> affect our     ability to market or sell Provenge or our other <font color="blue">potential product</font>s, if     approved</td>
    </tr>
    <tr>
      <td>Federal, state and <font color="blue">foreign <font color="blue">government</font>s continue</font> to <font color="blue">propose legislation</font>     designed to contain or <font color="blue">reduce health care costs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Legislation </font>and <font color="blue">regulations</font>     <font color="blue">affecting</font> the pricing of products like our <font color="blue">potential product</font>s may change     further or be adopted before Provenge or any of our <font color="blue">potential product</font>s are     approved for marketing</td>
    </tr>
    <tr>
      <td>Cost <font color="blue">control <font color="blue">initiatives</font> by <font color="blue">government</font>s</font> or third     <font color="blue">party payers could decrease</font> the price that we receive for any one or all of     our <font color="blue">potential product</font>s or <font color="blue">increase patient coinsurance</font> to a level that makes     Provenge and our other <font color="blue">products under</font> <font color="blue">development</font> unaffordable</td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">government</font> and <font color="blue">private health</font> plans <font color="blue">persistently challenge</font> the price and     cost-<font color="blue">effective</font>ness of <font color="blue"><font color="blue">therapeutic</font> products</font></td>
    </tr>
    <tr>
      <td>Accordingly, these <font color="blue">third parties</font>     <font color="blue">may ultimately</font> not consider Provenge or any or all of our <font color="blue">products under</font>     <font color="blue">development</font> to be cost-<font color="blue">effective</font>, which could result in products not being     <font color="blue">covered under</font> their health plans or <font color="blue">covered only at</font> a lower price</td>
    </tr>
    <tr>
      <td>Any of     these  <font color="blue">initiatives</font>  or <font color="blue">development</font>s could prevent us from <font color="blue">successfully</font>     marketing  and selling any of our <font color="blue">potential product</font>s</td>
    </tr>
    <tr>
      <td>We are unable to     predict  what  impact  the  <font color="blue">Medicare Modernization Act </font>or other future     regulation  or  third  party  payer  <font color="blue">initiatives</font>,  if any, relating to     <font color="blue">reimbursement</font> for Provenge or any of our other <font color="blue">potential product</font>s will have     on sales of Provenge or those other product <font color="blue">candidates</font>, if any of them are     approved for sale</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to Manufacturing Activities          We have no commercial or other large-scale <font color="blue">manufacturing</font> experience</td>
    </tr>
    <tr>
      <td>To  be  successful,  our  product  <font color="blue">candidates</font> must be capable of being     <font color="blue">manufacture</font>d  in  <font color="blue">sufficient quantities</font>, in <font color="blue">compliance with</font> <font color="blue">regulatory</font>     <font color="blue">requirements</font> and at an acceptable cost</td>
    </tr>
    <tr>
      <td>We have no commercial or other     large-scale <font color="blue">manufacturing</font> experience</td>
    </tr>
    <tr>
      <td>We currently rely on <font color="blue">third parties</font> for     <font color="blue">certain aspects</font> of the commercial and <font color="blue">clinical trial</font> <font color="blue">manufacture</font> of <font color="blue"><font color="blue">Provenge  </font>   </font>and its <font color="blue">components</font> and our other product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In August 2005, we     <font color="blue">entered into</font> a lease <font color="blue">agreement</font> for a <font color="blue">facility</font> in Hanover, New Jersey, which     will include commercial <font color="blue">manufacturing</font> space</td>
    </tr>
    <tr>
      <td>The build-out of this space     will require a substantial <font color="blue">investment</font> and is expected to <font color="blue">extend through</font>     mid-2006</td>
    </tr>
    <tr>
      <td>We will also be required to hire and train a <font color="blue">significant</font> number of     employees and <font color="blue">comply with</font>                                           22     ______________________________________________________________________       applicable <font color="blue">regulations</font> for these <font color="blue">facilities</font>, which are extensive</td>
    </tr>
    <tr>
      <td>A limited     number of contract <font color="blue"><font color="blue">manufacture</font>r</font>s are capable of <font color="blue">manufacturing</font> the <font color="blue">components</font>     of Provenge or the final <font color="blue">manufacture</font> of Provenge</td>
    </tr>
    <tr>
      <td>If we <font color="blue">encounter delays</font> or     <font color="blue">difficult</font>ies  with <font color="blue"><font color="blue">manufacture</font>r</font>s and cannot <font color="blue">manufacture</font> the contracted     <font color="blue">components</font> or <font color="blue">product candidate</font> ourselves, we may not be able to conduct     clinical  trials  as  planned or to meet demand for Provenge, if it is     approved, any of <font color="blue">which could harm</font> our business</td>
    </tr>
    <tr>
      <td>We will need to <font color="blue">demonstrate</font> that Provenge <font color="blue">manufacture</font>d at our new <font color="blue">facility</font>     is comparable to Provenge used in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">increased production efforts</font>, we may make <font color="blue">manufacturing</font>     changes to the <font color="blue">components</font> or to the <font color="blue">manufacturing</font> process for Provenge</td>
    </tr>
    <tr>
      <td>These  changes could result in delays in the <font color="blue">development</font> or <font color="blue">regulatory</font>     approval of Provenge or in reduction or <font color="blue">interruption</font> of <font color="blue">commercial sale</font>s, in     the event Provenge is approved, any of <font color="blue">which could <font color="blue">materially harm</font></font> our     business</td>
    </tr>
    <tr>
      <td>We will be required to <font color="blue">demonstrate</font> product comparability for each     <font color="blue">manufacturing</font> site</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">yet submitted</font> a plan for carrying out this     <font color="blue">comparability testing</font> to the <font color="blue">FDA The FDA </font><font color="blue">may disagree with</font> our plans or     require substantial <font color="blue">additional</font> testing beyond what we propose</td>
    </tr>
    <tr>
      <td>In addition,     we may not be able to <font color="blue">demonstrate</font> product comparability to <font color="blue">clinical trial</font>     materials</td>
    </tr>
    <tr>
      <td>We intend to rely on results of <font color="blue">preclinical studies</font> and <font color="blue"><font color="blue">clinical trial</font>s</font>     performed using the form of the <font color="blue">product candidate</font> produced using the prior     <font color="blue">formulation</font> or <font color="blue">production method</font> or at the prior scale</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon the     type and degree of differences between <font color="blue">manufacturing</font> processes or component     <font color="blue">substitutions</font>  for  a <font color="blue">product candidate</font>, we may be required to conduct     <font color="blue">additional</font> studies or <font color="blue"><font color="blue">clinical trial</font>s</font> to <font color="blue">demonstrate</font> that the new method(s)     or substitute component or <font color="blue">product candidate</font> is <font color="blue">sufficiently</font> similar to the     <font color="blue">previously</font> produced material</td>
    </tr>
    <tr>
      <td>We and our contract <font color="blue"><font color="blue">manufacture</font>r</font>s are subject to <font color="blue">significant</font> regulation with     respect to <font color="blue">manufacturing</font> of our products</td>
    </tr>
    <tr>
      <td>All of those involved in the <font color="blue">preparation</font> of a <font color="blue">therapeutic</font> drug for clinical     trials or <font color="blue">commercial sale</font>, including our existing contract <font color="blue"><font color="blue">manufacture</font>r</font> for     the  Antigen  Delivery  Cassette  used in Provenge, and <font color="blue">clinical trial</font>     <font color="blue">investigators</font>, are subject to extensive <font color="blue">regulation by</font> <font color="blue">the FDA Components </font>of     a finished <font color="blue">therapeutic</font> product approved for <font color="blue">commercial sale</font> or used in     late-stage <font color="blue"><font color="blue">clinical trial</font>s</font> must be <font color="blue">manufacture</font>d in <font color="blue">accordance</font> with cGMP, a     series  of complex <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> govern <font color="blue">manufacturing</font>     processes and procedures and the <font color="blue">implementation</font> and operation of quality     systems to control and assure the quality of <font color="blue">investigational</font> products and     <font color="blue">products approved</font> for sale</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facilities</font> and <font color="blue">quality systems</font> and the     <font color="blue">facilities</font> and <font color="blue">quality systems</font> of some or all of our <font color="blue">third party</font> <font color="blue">contractors</font>     must pass a pre-approval inspection for <font color="blue">compliance with</font> the applicable     <font color="blue">regulations</font> as a condition of FDA approval of Provenge or any of our other     <font color="blue">potential product</font>s</td>
    </tr>
    <tr>
      <td>In addition, the FDA may, at any time, audit or inspect     a <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facility</font></font> involved with the <font color="blue">preparation</font> of Provenge or our     other <font color="blue">potential product</font>s or the associated <font color="blue">quality systems</font> for compliance     with the <font color="blue">regulations</font> applicable to the <font color="blue">activities</font> being conducted</td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>also may, at any time <font color="blue">following approval</font> of a product for sale, audit our     <font color="blue">manufacturing</font> <font color="blue">facilities</font> or those of our <font color="blue">third party</font> <font color="blue">contractors</font></td>
    </tr>
    <tr>
      <td>If any     such inspection or audit identifies a failure to <font color="blue">comply with</font> applicable     <font color="blue">regulations</font> or if a violation of our product <font color="blue">specifications</font> or applicable     regulation occurs <font color="blue">independent</font> of such an inspection or audit, we <font color="blue">or the FDA </font>    may require <font color="blue">remedial measures</font> that may be costly and/or time consuming for     us or a <font color="blue">third party</font> to implement and that may include the temporary or     permanent  suspension  of  a <font color="blue">clinical trial</font> or <font color="blue">commercial sale</font>s or the     temporary or <font color="blue">permanent closure</font> of a <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Any such <font color="blue">remedial measures</font>     imposed  upon us or <font color="blue">third parties</font> with whom we <font color="blue">contract could harm</font> our     business</td>
    </tr>
    <tr>
      <td>If we make changes in our <font color="blue">manufacturing</font> processes for a <font color="blue">product candidate</font>,     or  change  <font color="blue">components</font>  of  a  drug, the FDA and <font color="blue">corresponding</font> foreign     <font color="blue">authorities</font> may require us to <font color="blue">demonstrate</font> that the changes have not caused     the <font color="blue">product candidate</font> to differ <font color="blue">significant</font>ly from that <font color="blue">previously</font> produced</td>
    </tr>
    <tr>
      <td><font color="blue">Expansion </font>of our production <font color="blue">capabilities</font> or <font color="blue">facilities</font> might also require     <font color="blue">reexamination</font> of our <font color="blue">manufacturing</font> processes</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       We  must  rely  at  present on <font color="blue">relationships</font> with third-party contract     <font color="blue"><font color="blue">manufacture</font>r</font>s, which will limit our ability to control the <font color="blue">availability</font> of,     and <font color="blue">manufacturing</font> costs for, our product <font color="blue">candidates</font> in the near-term</td>
    </tr>
    <tr>
      <td>We will rely upon contract <font color="blue"><font color="blue">manufacture</font>r</font>s for <font color="blue">components</font> of Provenge for     <font color="blue">commercial sale</font>, if it is approved for sale</td>
    </tr>
    <tr>
      <td>We have <font color="blue">contracts with contract</font>     <font color="blue"><font color="blue">manufacture</font>r</font>s for <font color="blue"><font color="blue">commercial level</font> production</font> for some, but not all, of     these <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>While we plan to <font color="blue">negotiate contracts</font> for <font color="blue">commercial level</font>     production with contract <font color="blue"><font color="blue">manufacture</font>r</font>s for all <font color="blue">components</font> that we do not     produce ourselves, there is no assurance that we will be able to do so on     acceptable terms or at all</td>
    </tr>
    <tr>
      <td>Failure to negotiate such contracts and to     maintain <font color="blue">sufficient capacity under</font> these <font color="blue">arrangements</font> for <font color="blue">manufacturing</font>     needs could cause <font color="blue">inventory shortfalls</font>, and delay or prevent the successful     <font color="blue">commercialization</font> of Provenge</td>
    </tr>
    <tr>
      <td>In  addition,  <font color="blue">problems with</font> any of our or our contract <font color="blue"><font color="blue">manufacture</font>r</font>s’     <font color="blue">facilities</font> or <font color="blue">processes could</font> result in failure to produce or a delay in     production of <font color="blue">adequate supplies</font> of antigen, <font color="blue">components</font> or finished Provenge</td>
    </tr>
    <tr>
      <td>This <font color="blue">could delay</font> or reduce <font color="blue">commercial sale</font>s and harm our business</td>
    </tr>
    <tr>
      <td>Any     prolonged  <font color="blue">interruption</font>  in  the  <font color="blue">operations</font>  of  our  or our contract     <font color="blue"><font color="blue">manufacture</font>r</font>s’ <font color="blue">facilities</font> could result in <font color="blue">cancellation</font> of shipments, loss of     <font color="blue">components</font>  in  the  process  of  being <font color="blue">manufacture</font>d or a shortfall in     <font color="blue">availability</font> of a product</td>
    </tr>
    <tr>
      <td>A number of factors could cause <font color="blue">interruption</font>s,     including the <font color="blue">inability</font> of a supplier to provide raw materials, equipment     <font color="blue">malfunctions</font> or failures, damage to a <font color="blue">facility</font> due to <font color="blue">natural disasters</font>,     changes  in  FDA  <font color="blue">regulatory</font>  <font color="blue">requirements</font>  or  standards that require     <font color="blue">modifications</font> to our <font color="blue">manufacturing</font> processes, <font color="blue">action by</font> the FDA or by us     that results in the halting or slowdown of production of <font color="blue">components</font> or     finished <font color="blue">product due</font> to <font color="blue">regulatory</font> issues, a contract <font color="blue"><font color="blue">manufacture</font>r</font> going out     of business or failing to produce <font color="blue">product as <font color="blue">contractual</font>ly</font> required or other     similar factors</td>
    </tr>
    <tr>
      <td>Because <font color="blue">manufacturing</font> processes are <font color="blue">highly complex</font> and are     subject to a lengthy FDA approval process, alternative qualified production     <font color="blue">capacity may</font> not be <font color="blue">available on</font> a <font color="blue">timely basis</font> or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties </font>or     delays in our contract <font color="blue"><font color="blue">manufacture</font>r</font>s’ <font color="blue">manufacturing</font> and supply of <font color="blue">components</font>     <font color="blue">could delay</font> <font color="blue">completion</font> of our BLA submission and <font color="blue"><font color="blue">clinical trial</font>s</font>, increase     our costs, damage our reputation and, for Provenge, if it is approved for     sale, cause us to <font color="blue">lose revenue</font> or market share if we are unable to timely     <font color="blue">meet market demands</font></td>
    </tr>
    <tr>
      <td>If  our  contract  <font color="blue"><font color="blue">manufacture</font>r</font>s are not in <font color="blue">compliance with</font> <font color="blue">regulatory</font>     <font color="blue">requirements</font> at any stage, including post-marketing approval, we may be     fined, forced to remove a <font color="blue">product from</font> the market and/or experience other     <font color="blue">adverse consequences</font>, including delays, <font color="blue">which could <font color="blue">materially harm</font></font> our     financial results</td>
    </tr>
    <tr>
      <td>We  use  <font color="blue">hazardous</font>  materials  in  our  business  and must <font color="blue">comply with</font>     <font color="blue">environmental laws</font> and <font color="blue">regulations</font>, which can be expensive</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> produce <font color="blue">hazardous</font> waste products, including <font color="blue">chemicals</font> and     <font color="blue">radioactive</font>  and  <font color="blue">biological materials</font></td>
    </tr>
    <tr>
      <td>We are subject to a variety of     federal, state and local <font color="blue">regulations</font> relating to the use, handling, storage     and  disposal  of these materials</td>
    </tr>
    <tr>
      <td>Although we believe that our safety     procedures for handling and disposing of these <font color="blue">materials complies with</font> the     standards  prescribed  by  state  and federal <font color="blue">regulations</font>, the risk of     <font color="blue">accidental</font>  <font color="blue">contamination</font>  or  injury  from  these <font color="blue">materials cannot</font> be     eliminated</td>
    </tr>
    <tr>
      <td>We generally contract with <font color="blue">third parties</font> for the disposal of     <font color="blue">such substances</font> and store our low level <font color="blue">radioactive</font> waste at our <font color="blue">facilities</font>     until the materials are no longer considered <font color="blue">radioactive</font></td>
    </tr>
    <tr>
      <td>We may be required     to <font color="blue">incur further costs</font> to <font color="blue">comply with</font> current or <font color="blue">future environmental</font> and     safety <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In addition, in the event of <font color="blue">accidental</font> <font color="blue">contamination</font> or     <font color="blue">injury from</font> these materials, we could be held liable for any damages that     result and any <font color="blue">such <font color="blue">liability</font> could exceed</font> our resources</td>
    </tr>
    <tr>
      <td>Risks from Competitive Factors          Our <font color="blue"><font color="blue">competitors</font> may</font> develop and <font color="blue">market products</font> that are <font color="blue">less expensive</font>,     more <font color="blue">effective</font>, safer or reach the market sooner, which may diminish or     eliminate the <font color="blue">commercial success</font> of any products we may <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the cancer <font color="blue">therapeutic</font>s field is intense and is <font color="blue">accentuated</font>     by the rapid pace of <font color="blue"><font color="blue">advancement</font>s</font> in product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We anticipate that     we <font color="blue">will face increased competition</font> in the <font color="blue">future as new companies enter</font> our     markets</td>
    </tr>
    <tr>
      <td>Some <font color="blue">competitors</font> are pursuing a product <font color="blue">development</font> strategy     <font color="blue">competitive with ours</font></td>
    </tr>
    <tr>
      <td><font color="blue">Certain                                           </font>24     ______________________________________________________________________       of these <font color="blue">competitive <font color="blue">products may</font></font> be in a more <font color="blue">advanced stage</font> of product     <font color="blue">development</font>  and  clinical  trials</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">compete with</font> other     clinical-stage companies and <font color="blue">institutions</font> for <font color="blue">clinical trial</font> <font color="blue">participants</font>,     <font color="blue">which could reduce</font> our ability to <font color="blue">recruit <font color="blue">participants</font></font> for our clinical     trials</td>
    </tr>
    <tr>
      <td>Delay in recruiting <font color="blue">clinical trial</font> <font color="blue">participants</font> could <font color="blue">adversely</font>     affect our ability to bring a product to market prior to our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Further, research and <font color="blue">discoveries by others may</font> result in <font color="blue">breakthroughs</font> that     render Provenge or our other <font color="blue">potential product</font>s obsolete even before they     begin to generate any revenue</td>
    </tr>
    <tr>
      <td>There are <font color="blue">products currently</font> under <font color="blue">development</font> by others that <font color="blue">could compete</font>     with Provenge or other products that we are developing</td>
    </tr>
    <tr>
      <td>and <font color="blue">Therion Biologics Corporation </font>are developing prostate     cancer <font color="blue">therapeutic</font>s that <font color="blue">could potentially</font> <font color="blue">compete with</font> Provenge</td>
    </tr>
    <tr>
      <td>Therion     Biologics Corporation has completed <font color="blue">enrollment</font> in a Phase 2 <font color="blue">clinical trial</font>     of its prostate cancer <font color="blue">immunotherapy</font> and plans to initiate a Phase 3 trial     in 2006</td>
    </tr>
    <tr>
      <td>Cell Genesys, Inc</td>
    </tr>
    <tr>
      <td>has initiated Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font> of its     prostate cancer <font color="blue">immunotherapy</font></td>
    </tr>
    <tr>
      <td>Other products such as chemo<font color="blue">therapeutic</font>s,     antisense compounds, angiogenesis inhibitors and <font color="blue">gene therapies</font> for cancer     are also under <font color="blue">development</font> by a number of companies and <font color="blue">could potentially</font>     <font color="blue">compete with</font> Provenge and our other product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>A chemo<font color="blue">therapeutic</font>,     Taxotere, was <font color="blue">approved by</font> the FDA in 2004 for the <font color="blue">therapeutic</font> treatment of     metastatic androgen-<font color="blue">independent</font> prostate cancer</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> in the cancer <font color="blue">therapeutic</font>s field have <font color="blue">substantially</font>     <font color="blue">greater research</font> and <font color="blue">development</font> <font color="blue">capabilities</font> and <font color="blue">manufacturing</font>, marketing,     financial and <font color="blue">managerial resources than</font> we do</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">competitors</font>     may obtain <font color="blue">patent protection</font> or FDA approval and <font color="blue">commercialize</font> products more     <font color="blue">rapidly than</font> we do, <font color="blue">which may impact future sales</font> of our products</td>
    </tr>
    <tr>
      <td>If we are     <font color="blue">permitted by</font> the FDA to commence <font color="blue">commercial sale</font>s of products, we will also     be  competing <font color="blue">with respect</font> to marketing <font color="blue">capabilities</font> and <font color="blue">manufacturing</font>     <font color="blue">efficiency</font>, areas in which we have limited or no experience</td>
    </tr>
    <tr>
      <td>We expect that     competition among <font color="blue">products approved</font> for sale will be based, among other     things, on product efficacy, price, safety, re<font color="blue">liability</font>, <font color="blue">availability</font>,     <font color="blue">patent protection</font>, and sales, marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">profitability</font> and <font color="blue">financial position will suffer</font> if our products receive     <font color="blue">regulatory</font> approval, but cannot compete <font color="blue">effective</font>ly in the marketplace</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may</font> not be accepted in the marketplace; therefore, we may not     be able to generate <font color="blue">significant</font> revenue, if any</td>
    </tr>
    <tr>
      <td>Even if Provenge or any of our other <font color="blue">potential product</font>s is approved and     sold, physicians and the <font color="blue"><font color="blue">medical community</font> may</font> not <font color="blue">ultimately use</font> it or may     use it only in <font color="blue">application</font>s more <font color="blue">restricted than</font> we expect</td>
    </tr>
    <tr>
      <td>Our products, if     <font color="blue">successfully</font> developed, will <font color="blue">compete with</font> a number of <font color="blue">traditional products</font>     and <font color="blue">immunotherapies</font> <font color="blue">manufacture</font>d and <font color="blue">marketed by major pharmaceutical</font> and     other bio<font color="blue">technology</font> companies</td>
    </tr>
    <tr>
      <td>Our products will also <font color="blue">compete with</font> new     products  currently  under  <font color="blue">development</font>  <font color="blue">by such companies</font> and others</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians  </font>will  <font color="blue">only prescribe</font> a product if they determine, <font color="blue">based on</font>     experience, <font color="blue">clinical data</font>, side effect profiles and other factors, that it     is <font color="blue">beneficial</font> and preferable to other <font color="blue">products currently</font> in use</td>
    </tr>
    <tr>
      <td>Many other     factors influence the adoption of new products, including marketing and     <font color="blue">distribution</font> <font color="blue">restrictions</font>, course of treatment, adverse publicity, product     pricing,  the  views  of thought leaders in the <font color="blue">medical community</font>, and     <font color="blue">reimbursement</font> by <font color="blue">government</font> and private <font color="blue">third party</font> payers</td>
    </tr>
    <tr>
      <td>Failure to retain <font color="blue">key personnel</font> could impede our ability to develop our     products and to obtain new <font color="blue">collaboration</font>s or other sources of funding</td>
    </tr>
    <tr>
      <td>We depend, to a <font color="blue">significant</font> extent, on the efforts of our <font color="blue">key employees</font>,     including senior <font color="blue">management</font> and senior scientific, clinical, <font color="blue">regulatory</font> and     other  personnel</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of new <font color="blue"><font color="blue">therapeutic</font> products</font> requires     <font color="blue">expertise from</font> a number of <font color="blue">different disciplines</font>, some of which are not     widely  available</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend upon</font> our <font color="blue">scientific staff</font> to <font color="blue">discover new</font>     product <font color="blue">candidates</font> and to develop and conduct <font color="blue">preclinical studies</font> of those     new <font color="blue">potential product</font>s</td>
    </tr>
    <tr>
      <td>Our clinical and <font color="blue">regulatory</font> staff is responsible for     the  design  and  execution  of <font color="blue"><font color="blue">clinical trial</font>s</font> in <font color="blue">accordance</font> with FDA     <font color="blue">requirements</font> and for the <font color="blue">advancement</font> of our product <font color="blue">candidates</font> toward FDA     approval  and  submission of <font color="blue">data supporting approval</font></td>
    </tr>
    <tr>
      <td>The quality and     reputation of our scientific, clinical and <font color="blue">regulatory</font> staff,                                           25     ______________________________________________________________________       <font color="blue">especially</font>  the  senior  staff,  and their success in performing their     <font color="blue">responsibilities</font>,  may  directly  influence the success of our product     <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">Chief Executive Officer </font>and other     <font color="blue">executive officers</font> are involved in a <font color="blue">broad range</font> of critical <font color="blue">activities</font>,     including <font color="blue">providing strategic</font> and <font color="blue">operational guidance</font></td>
    </tr>
    <tr>
      <td>The loss of these     <font color="blue">individuals</font>, or our <font color="blue">inability</font> to retain or recruit other key <font color="blue">management</font> and     scientific, clinical, <font color="blue">regulatory</font> and other personnel, may delay or prevent     us from achieving our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense competition</font> for     <font color="blue">personnel from</font> other companies, universities, public and <font color="blue">private research</font>     <font color="blue">institutions</font>, <font color="blue">government</font> entities and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to Collaboration Arrangements          If we fail to <font color="blue">enter into</font> any needed <font color="blue">collaboration</font> <font color="blue">agreement</font>s for our product     <font color="blue">candidates</font>, we may be unable to <font color="blue">commercialize</font> them <font color="blue">effective</font>ly or at all</td>
    </tr>
    <tr>
      <td>To <font color="blue">successfully</font> <font color="blue">commercialize</font> Provenge, we will need substantial financial     resources and we will need to develop or <font color="blue">access expertise</font> and physical     resources and systems, including <font color="blue">building out</font> our <font color="blue">manufacturing</font> <font color="blue">facilities</font>,     a <font color="blue">distribution</font> network, an information <font color="blue">technology</font> platform and sales and     marketing and other resources that we currently do not have or may be in the     process of developing</td>
    </tr>
    <tr>
      <td>We may elect to develop some or all of these physical     resources and systems and <font color="blue">expertise ourselves</font> or we may seek to <font color="blue">collaborate</font>     with another bio<font color="blue">technology</font> or <font color="blue">pharmaceutical company</font> that can provide some     or all of <font color="blue">such <font color="blue">physical resources</font></font> and <font color="blue">systems as well as <font color="blue">financial resources</font></font>     and expertise</td>
    </tr>
    <tr>
      <td>Such <font color="blue">collaboration</font>s are complex and any potential <font color="blue">discussions</font>     may not result in a definitive <font color="blue">agreement</font> for many reasons</td>
    </tr>
    <tr>
      <td>For example,     whether we reach a definitive <font color="blue">agreement</font> for a <font color="blue">collaboration</font> will depend,     among other things, upon our <font color="blue">assessment</font> of the <font color="blue">collaborator</font>’s resources and     expertise, the terms and <font color="blue">conditions</font> of the proposed <font color="blue">collaboration</font>, and the     proposed <font color="blue">collaborator</font>’s evaluation of a number of factors</td>
    </tr>
    <tr>
      <td>Those <font color="blue">factors may</font>     include the design or results of our Provenge <font color="blue"><font color="blue">clinical trial</font>s</font>, the potential     market  for Provenge,  the costs and <font color="blue">complexities</font> of <font color="blue">manufacturing</font> and     delivering Provenge to patients, the potential of <font color="blue">competing products</font>, the     existence of <font color="blue">uncertainty</font> <font color="blue">with respect</font> to our ownership of <font color="blue">technology</font>, which     can exist if there is a challenge to such ownership without regard to the     merits of the challenge and industry and market <font color="blue">conditions</font> generally</td>
    </tr>
    <tr>
      <td>If we     were to determine that a <font color="blue">collaboration</font> for Provenge is <font color="blue">necessary</font> and were     unable to <font color="blue">enter into</font> such a <font color="blue">collaboration</font> on acceptable terms, we might     elect to delay or scale back the <font color="blue">commercialization</font> of Provenge in order to     preserve our <font color="blue">financial resources</font> or to <font color="blue">allow us adequate</font> time to develop the     required <font color="blue">physical resources</font> and systems and <font color="blue">expertise ourselves</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">enter into</font> a <font color="blue">collaboration</font> <font color="blue">agreement</font> we consider acceptable, the     <font color="blue">collaboration</font> may not proceed as quickly, smoothly or <font color="blue">successfully</font> as we     plan</td>
    </tr>
    <tr>
      <td>The risks in a <font color="blue">collaboration</font> <font color="blue">agreement</font> for Provenge include the     following:           •   the <font color="blue">collaborator</font> may not apply the expected <font color="blue">financial resources</font> or     required expertise in developing the <font color="blue">physical resources</font> and systems     <font color="blue">necessary</font> to <font color="blue">successfully</font> <font color="blue">commercialize</font> Provenge;           •   the <font color="blue">collaborator</font> may not invest in the <font color="blue">development</font> of a sales and     <font color="blue">marketing force</font> and the related <font color="blue">infrastructure</font> at levels that ensure that     sales of Provenge reach their full potential;           •   <font color="blue">disputes may</font> arise <font color="blue">between us</font> and a <font color="blue">collaborator</font> that delay the     <font color="blue">commercialization</font> of Provenge or <font color="blue">adversely</font> affect its sales or     <font color="blue">profitability</font>; or           •   the <font color="blue">collaborator</font> may <font color="blue">independent</font>ly develop, or develop with third     parties, products that could <font color="blue">compete with</font> Provenge</td>
    </tr>
    <tr>
      <td>With respect to a <font color="blue">collaboration</font> for Provenge or any of our other product     <font color="blue">candidates</font>,  we  are  <font color="blue">dependent on</font> the success of our <font color="blue"><font color="blue">collaborator</font>s</font> in     performing their respective <font color="blue">responsibilities</font> and the <font color="blue">continued cooperation</font>     of our <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">collaborator</font>s</font> may not <font color="blue">cooperate with us</font> to perform     their <font color="blue">obligations</font> under our <font color="blue">agreement</font>s with them</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot control</font> the     amount and timing of our <font color="blue"><font color="blue">collaborator</font>s</font>’ resources that will be devoted to     <font color="blue">activities</font>  related  to  our  <font color="blue">collaborative</font>  <font color="blue">agreement</font>s with them</td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">collaborator</font>s</font> may choose to <font color="blue">pursue existing</font> or alternative <font color="blue">technologies</font> in     preference to those being developed in <font color="blue">collaboration</font> with us</td>
    </tr>
    <tr>
      <td>Disputes may     arise                                           26     ______________________________________________________________________       between  us  and  our  <font color="blue"><font color="blue">collaborator</font>s</font>  that  delay  the <font color="blue">development</font> and     <font color="blue">commercialization</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In addition, a <font color="blue">collaborator</font> for     <font color="blue">Provenge  </font>may  have  the  right  to terminate the <font color="blue">collaboration</font> at its     <font color="blue">discretion</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">termination may</font> require us to seek a new <font color="blue">collaborator</font>, which     we may not be able to do on a <font color="blue">timely basis</font>, if at all, or require us to     delay or scale back the <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>The occurrence of any of     these events could <font color="blue">adversely</font> affect the <font color="blue">commercialization</font> of Provenge and     harm our business and stock price by delaying the date on which sales of the     <font color="blue">product may</font> begin, if it is <font color="blue">approved by</font> the FDA, by slowing the pace of     growth of such sales, by reducing the <font color="blue">profitability</font> of the product or by     <font color="blue">adversely</font> <font color="blue">affecting</font> the reputation of the product in the market</td>
    </tr>
    <tr>
      <td>We have <font color="blue">existing <font color="blue">collaboration</font></font> <font color="blue">agreement</font>s that may not achieve the desired     results, or <font color="blue">could terminate abruptly</font></td>
    </tr>
    <tr>
      <td>We have a <font color="blue">collaboration</font> with Genentech, Inc</td>
    </tr>
    <tr>
      <td>for the research, <font color="blue">development</font>     and <font color="blue">commercialization</font> of potential therapies targeting trp-p8</td>
    </tr>
    <tr>
      <td>We also have     a  <font color="blue">collaboration</font>  with Abgenix, Inc</td>
    </tr>
    <tr>
      <td>for the research, <font color="blue">development</font> and     <font color="blue">commercialization</font> of <font color="blue">monoclonal antibodies</font> for a <font color="blue">selected antigen from</font> our     portfolio  of <font color="blue">serine proteases</font></td>
    </tr>
    <tr>
      <td>It is possible that we could encounter     <font color="blue">difficult</font>ies  with these <font color="blue"><font color="blue">collaborator</font>s</font> in the future that could have a     material adverse effect on our business</td>
    </tr>
    <tr>
      <td><font color="blue">Risks in Protecting </font>our Intellectual Property          If we are unable to protect our <font color="blue">proprietary rights</font> or to <font color="blue">defend against</font>     <font color="blue">infringement</font> claims, we may not be able to compete <font color="blue">effective</font>ly or operate     profitably</td>
    </tr>
    <tr>
      <td>We invent and develop <font color="blue">technologies</font> that are the basis for or <font color="blue">incorporated</font> in     our <font color="blue">potential product</font>s</td>
    </tr>
    <tr>
      <td>We protect our <font color="blue">technology</font> through <font color="blue">United States </font>and     foreign patent filings, trademarks and <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We have a number of     <font color="blue">issued patents</font>, and <font color="blue">application</font>s for US and foreign patents in various     stages of <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>We expect that we <font color="blue">will continue</font> to file and prosecute     patent <font color="blue">application</font>s and that our <font color="blue">success depends</font> in part on our ability to     establish and defend our <font color="blue">proprietary rights</font> in the <font color="blue">technologies</font> that are the     subject of <font color="blue">issued patents</font> and patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>The  fact that we have filed a patent <font color="blue">application</font> or that a patent has     issued, however, does not ensure that we will have <font color="blue">meaningful protection</font>     from  <font color="blue">competition with</font> regard to the underlying <font color="blue">technology</font> or product</td>
    </tr>
    <tr>
      <td>Patents, if issued, may be challenged, invalidated, declared unenforceable     or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>In addition, our pending patent <font color="blue">application</font>s as well as     those we may file in the <font color="blue">future may</font> not result in <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td><font color="blue">Patents     </font>may  not <font color="blue">provide us with adequate proprietary protection</font> or <font color="blue">advantages</font>     against  <font color="blue">competitors</font>  with, or who could develop, similar or competing     <font color="blue">technologies</font> or who <font color="blue">could design around</font> our patents</td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on <font color="blue">trade secrets</font></font> and unpatentable know-how that we seek to     protect, in part, by using <font color="blue">confidential</font>ity <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Our policy is to     require our officers, employees, consultants, <font color="blue">contractors</font>, <font color="blue"><font color="blue">manufacture</font>r</font>s,     outside  scientific  <font color="blue"><font color="blue">collaborator</font>s</font> and <font color="blue">sponsored researchers</font> and other     advisors to execute <font color="blue">confidential</font>ity <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s provide     that all <font color="blue">confidential</font> information developed or made known to the individual     during  the  course  of  the individual’s relationship with us be kept     <font color="blue">confidential</font> and not disclosed to <font color="blue">third parties</font> except in specific limited     <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>We also require signed <font color="blue">confidential</font>ity <font color="blue">agreement</font>s from     companies that receive our <font color="blue">confidential</font> data</td>
    </tr>
    <tr>
      <td>For employees, consultants and     <font color="blue">contractors</font>,  we require <font color="blue">confidential</font>ity <font color="blue">agreement</font>s providing that all     <font color="blue">inventions</font> conceived while rendering services to us shall be assigned to us     as our <font color="blue">exclusive property</font></td>
    </tr>
    <tr>
      <td>It is possible, however, that these <font color="blue">parties may</font>     breach those <font color="blue">agreement</font>s, and we may not have <font color="blue">adequate remedies</font> for any     breach</td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that our <font color="blue">trade secrets</font> or unpatentable know-how     <font color="blue">will otherwise become known</font> to or be <font color="blue">independent</font>ly developed by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>From time to time, we have received <font color="blue">invitations</font> to license <font color="blue">third party</font>     patents</td>
    </tr>
    <tr>
      <td>We are also subject to the risk of claims, <font color="blue">whether meritorious</font> or     not, that our <font color="blue">immunotherapy</font> <font color="blue">candidates</font> infringe or <font color="blue">misappropriate third</font>     party  <font color="blue">intellectual</font>  property  rights</td>
    </tr>
    <tr>
      <td>If we are found to infringe or     misappropriate <font color="blue">third party</font> <font color="blue">intellectual</font> property, we                                           27     ______________________________________________________________________       could be required to seek a license or <font color="blue">discontinue</font> our products or cease     using  certain <font color="blue">technologies</font> or delay <font color="blue">commercialization</font> of the affected     product(s), and we could be required to pay substantial damages, which could     <font color="blue">materially harm</font> our business</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">litigation</font> that will be costly to defend or pursue and     uncertain in its outcome</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">may bring us into conflict with</font> our licensees, licensors or     others with whom we have <font color="blue">contractual</font> or other business <font color="blue">relationships</font>, or     with our <font color="blue">competitors</font> or <font color="blue">others whose interests differ from ours</font></td>
    </tr>
    <tr>
      <td>If we are     unable to resolve those <font color="blue">conflicts on terms</font> that are satisfactory to all     parties, we <font color="blue">may become involved</font> in <font color="blue">litigation</font> brought by or <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td><font color="blue">That     </font><font color="blue">litigation</font> is likely to be expensive and may require a <font color="blue">significant</font> amount of     <font color="blue">management</font>’s time and attention, at the expense of other aspects of our     business</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>relating to the ownership and use of <font color="blue">intellectual</font> property is     expensive, and our <font color="blue">position as</font> a <font color="blue">relatively</font> small company in an industry     <font color="blue">dominated by</font> very large <font color="blue">companies may</font> cause us to be at a <font color="blue">disadvantage</font> in     defending our <font color="blue">intellectual</font> property rights and in <font color="blue">defending against</font> claims     that our <font color="blue">immunotherapy</font> <font color="blue">candidates</font> infringe or misappropriate <font color="blue">third party</font>     <font color="blue">intellectual</font> property rights</td>
    </tr>
    <tr>
      <td>Even if we are able to defend our position,     the cost of doing so may <font color="blue">adversely</font> affect our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have not yet     experienced patent <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>This may reflect, however, the fact that we     have not yet <font color="blue">commercialize</font>d any products</td>
    </tr>
    <tr>
      <td>We may in the future be subject to     such <font color="blue">litigation</font> and may not be able to protect our <font color="blue">intellectual</font> property at     a <font color="blue">reasonable cost</font> if such <font color="blue">litigation</font> is initiated</td>
    </tr>
    <tr>
      <td>The outcome of <font color="blue">litigation</font>     is <font color="blue">always uncertain</font>, and in some <font color="blue">cases could</font> include judgments <font color="blue">against us</font>     that  require  us to pay damages, enjoin us from certain <font color="blue">activities</font> or     otherwise  affect  our legal or <font color="blue">contractual</font> rights, which could have a     <font color="blue">significant</font> adverse effect on our business</td>
    </tr>
    <tr>
      <td>We are exposed to <font color="blue">potential product</font> <font color="blue">liability</font> claims, and insurance against     these claims may not be available to us at a <font color="blue">reasonable rate</font> in the future</td>
    </tr>
    <tr>
      <td>Our  business <font color="blue">exposes us</font> to <font color="blue">potential product</font> <font color="blue">liability</font> risks that are     inherent in the testing, <font color="blue">manufacturing</font>, marketing and sale of <font color="blue">therapeutic</font>     products</td>
    </tr>
    <tr>
      <td>We have <font color="blue">clinical trial</font> insurance coverage, and we intend to obtain     <font color="blue">commercial product <font color="blue">liability</font> insurance coverage</font> in the future</td>
    </tr>
    <tr>
      <td>However, this     insurance  coverage  may not be adequate to cover claims <font color="blue">against us</font> or     available to us at an acceptable cost, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of their merit     or eventual outcome, product <font color="blue">liability</font> claims may result in decreased demand     for  a product, injury to our reputation, withdrawal of <font color="blue">clinical trial</font>     volunteers and loss of revenues</td>
    </tr>
    <tr>
      <td>Thus, whether or not we are insured, a     product <font color="blue">liability</font> claim or <font color="blue">product recall may</font> result in losses that could be     material</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to an Investment in Our Common Stock          Market  <font color="blue">volatility</font>  may  affect our stock price, and the value of your     <font color="blue">investment</font> in our <font color="blue">common stock</font> may be subject to <font color="blue">sudden decreases</font></td>
    </tr>
    <tr>
      <td>The  trading  price for our <font color="blue">common stock</font> has been, and we expect it to     continue to be, volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">price at which</font> our <font color="blue">common stock</font> trades depends     on a number of factors, including the following, many of which are beyond     our control:           •   timing and outcome of FDA review of our product <font color="blue">development</font> <font color="blue">activities</font>     and our <font color="blue">BLA for Provenge </font>that we intend to submit;           •   preclinical and <font color="blue">clinical trial</font> results;           •   our historical and anticipated operating results, including     <font color="blue">fluctuations</font> in our financial and operating results;           •   changes in <font color="blue">government</font> <font color="blue">regulations</font> <font color="blue">affecting</font> product approvals,     <font color="blue">reimbursement</font> or other aspects of our or our <font color="blue">competitors</font>’ businesses;           •   <font color="blue">announcements</font> of <font color="blue">technological innovations</font> or <font color="blue">new commercial products</font>     by us or our <font color="blue">competitors</font>;                                           28     ______________________________________________________________________         •   <font color="blue">development</font>s concerning our <font color="blue">key personnel</font> and <font color="blue">intellectual</font> property     rights;           •   <font color="blue">announcements</font> regarding <font color="blue">significant</font> <font color="blue">collaboration</font>s or strategic     alliances;           •   publicity regarding actual or <font color="blue">potential performance</font> of <font color="blue">products under</font>     <font color="blue">development</font> by us or our <font color="blue">competitors</font>;           •   <font color="blue">market perception</font> of the prospects for bio<font color="blue">technology</font> companies as an     industry sector; and           •   <font color="blue">general market</font> and economic <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> has from time to time experienced extreme     price and volume <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>These broad market <font color="blue">fluctuations</font> may lower the     <font color="blue">market price</font> of our <font color="blue">common stock</font> and affect the volume of trading in our     stock</td>
    </tr>
    <tr>
      <td>The high and <font color="blue">low intraday prices per</font> share of our <font color="blue">common stock</font> on the     <font color="blue">Nasdaq National Market </font>were dlra10dtta50 and dlra1dtta26 respectively in 2002, dlra10dtta50     and dlra4dtta01 respectively in 2003, dlra16dtta72 and dlra7dtta23 respectively in 2004, and     dlra11dtta04 and dlra4dtta31 respectively in 2005</td>
    </tr>
    <tr>
      <td>The <font color="blue">average daily trading volume</font> of     our <font color="blue">common stock</font> on the <font color="blue">Nasdaq National Market </font>was 132cmam760 shares in 2002,     669cmam347 shares in 2003, and 1cmam344cmam235 shares in 2004, and 1cmam270cmam008 shares     in 2005</td>
    </tr>
    <tr>
      <td>During periods of stock <font color="blue">market price</font> <font color="blue">volatility</font>, share prices of     many  bio<font color="blue">technology</font>  companies  have  <font color="blue">often fluctuated</font> in a manner not     <font color="blue">necessarily</font> related to their individual operating performance</td>
    </tr>
    <tr>
      <td>Accordingly,     our <font color="blue">common stock</font> may be subject to greater price <font color="blue">volatility</font> than the stock     <font color="blue">market as</font> a whole</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our <font color="blue">charter documents</font> and under <font color="blue">Delaware </font>law and     our <font color="blue">stockholders</font>’ rights plan could make an <font color="blue">acquisition</font> of us, which may be     <font color="blue">beneficial</font> to our <font color="blue">stockholders</font>, more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws will make it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us on terms not <font color="blue">approved by</font> our board     of <font color="blue">directors</font> and may have the effect of <font color="blue">deterring hostile takeover attempts</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> authorizes our board of <font color="blue">directors</font> to issue     up to 10cmam000cmam000 shares of <font color="blue">preferred stock</font>, of which 1cmam000cmam000 shares have     <font color="blue">been designated as</font> “Series A Junior Participating Preferred Stock,” and to     fix the price, rights, preferences, privileges and <font color="blue">restrictions</font>, including     <font color="blue">voting rights</font>, of those <font color="blue">shares without</font> any <font color="blue">further vote</font> or <font color="blue">action by</font> the     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The rights of the holders of our <font color="blue">common stock</font> will be subject     to, and may be junior to the rights of the holders of any <font color="blue">preferred stock</font>     that may be issued in the future</td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock</font> could     reduce  the  voting  power  of the holders of our <font color="blue">common stock</font> and the     likelihood that <font color="blue">common stock</font>holders will receive <font color="blue">payments upon liquidation</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">certificate</font> of <font color="blue">incorporation</font> divides our board of <font color="blue">directors</font>     <font color="blue">into three classes</font> having <font color="blue">staggered terms</font></td>
    </tr>
    <tr>
      <td>This may delay any attempt to     replace our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">also implemented</font> a <font color="blue">stockholders</font>’     rights plan, also called a poison pill, <font color="blue">which would</font> <font color="blue">substantially</font> reduce or     eliminate the expected <font color="blue">economic benefit</font> to an <font color="blue">acquirer from</font> acquiring us in     a manner or on terms not <font color="blue">approved by</font> our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These and other     <font color="blue">impediments</font> to a <font color="blue">third party</font> <font color="blue">acquisition</font> or change of <font color="blue">control could limit</font>     the <font color="blue">price investors</font> are willing to pay in the future for shares of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> adopted a Change of Control Executive     Severance Plan <font color="blue">providing severance benefits</font> for <font color="blue">participants</font> in the event     that their <font color="blue">employment terminates involuntarily without</font> cause or for good     <font color="blue">reason within twelve months</font> after a change of control of us</td>
    </tr>
    <tr>
      <td>This plan could     affect the terms of a <font color="blue">third party</font> <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>We are also subject to provisions of <font color="blue">Delaware </font>law that could have the effect     of delaying, deferring or preventing a change in control of our company</td>
    </tr>
    <tr>
      <td>One     of these provisions prevents us from engaging in a business <font color="blue">combination with</font>     any <font color="blue">interested stockholder</font> for a period of <font color="blue">three years from</font> the date the     person becomes an <font color="blue">interested stockholder</font>, unless specified <font color="blue">conditions</font> are     satisfied</td>
    </tr>
  </tbody>
</table>